GCC pharmacovigilance is evolving with digital tools, patient-centric focus, and strict compliance to SFDA GVP and UAE MoHAP guidelines, enhancing drug safety, risk management, and market access.
Innovative Pharmacovigilance in the GCC: Digital, Patient-Centric, Compliant Read More »
This blueprint guides building compliant pharmacovigilance systems in the Middle East/GCC by navigating regional regulations, establishing robust QMS, validating safety databases, and ensuring operational excellence in safety reporting.
Pharma firms face complex, varying regulatory challenges in the Middle East and GCC, especially with SFDA and EDA. PharmaOasis offers expert guidance, streamlined approvals, vigilance, and lifecycle management to ensure sustainable market access.
